Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766)
Cat# E3384-75E-100ug
Size : 100ug
Brand : US Biological
E3384-75E Rabbit Anti-Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766)
Clone Type
PolyclonalHost
mouseSource
humanSwiss Prot
O95278Isotype
IgG2bGrade
Affinity PurifiedApplications
WBCrossreactivity
HuShipping Temp
Blue IceStorage Temp
-20°CLaforin, also known as Lafora PTPase and EPM2A, is a 38kD member of the protein tyrosine phosphatase family. Human Laforin is 331 aa in length and contains one carbohydrate binding type-20 (CBM20) domain (aa 1-124) and one tyrosine-protein phosphatase domain (aa 243-311). Multiple splicing variants produce four isoforms of human Laforin, which is most highly expressed in heart, skeletal muscle, kidney, pancreas and brain. It functions as a dual specificity protein phosphatase and may be involved in the control of glycogen metabolism. Mutations in Laforin cause progressive myoclonic epilepsy type 2, also known as Lafora disease. | |Applications:|Suitable for use in RIA, Immunofluorescence, Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, Immunohistochemistry, Immunocytochemistry. Other applications not tested.||Recommended Dilution:|Western Blot: 1ug/ml|Optimal dilutions to be determined by the researcher.||Storage and Stability:|Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute by adding sterile 40-50% glycerol, aliquot and store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.